Two Products of Zhaoke Ophthalmology (6622.HK) Passes On-Site Inspection for Drug Registration by National Medical Products Administration and GMP Compliance Inspection by Guangdong Medical Products Administration
Signifying Government Recognition in The Company's Quality Manufacturing System
HONG KONG, May 24, 2021 - (ACN Newswire) - Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced that on 13 May 2021, two pharmaceutical products of the Company, namely Bimatoprost Timolol eye drop (a potential first-to-market generic drug in China targeting glaucoma, a fixed dose combination of a prostaglandin analogue and a beta-blocker) and Epinastine HCl eye drop (a potential first-to-market generic drug in China targeting allergic conjunctivitis with a dual mechanism of action of anti-histamine and mast cell stabilization), passed the on-site inspection for drug registration of the Greater Bay Area Center for Drug Evaluation of NMPA. The inspection verified the original records and information on the research and development as well as the manufacturing processes of the above two drug products.
The Company also passed the Good Manufacturing Practice (GMP) compliance inspection conducted by the Guangdong Medical Products Administration. It confirms that the Company has put in place a GMP management framework, a core team, a complete set of analytical instruments, equipment and facilities, a well-managed documentation system and proper operations of the production and quality systems.
Passing the on-site inspection for drug registration and GMP compliance is a major milestone for the Company. The positive result of the on-site inspection for drug registration of the Company as the first by any enterprise to complete such inspection conducted by the Greater Bay Area Center for Drug Evaluation of NMPA signifies NMPA's approval of the capacity of the Company's drug research and development system as well as the quality management system. It also validates that such systems can produce products compliant with the registration requirements in a sustained and consistent fashion.
The Company's manufacturing facility occupies approximately 7,600 sq.m. in Nansha New District, Guangzhou. It is designed and built for ophthalmic drugs in compliance with cGMP requirements of China, the United States and the EU with full manufacturing capability and ready for commercial-scale production. The Company is currently expanding its manufacturing capacity and expects to complete the expansion by the end of 2022.
Dr. Li Xiaoyi, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, "The eye is a very sensitive organ of the human body, so we attach great importance to our production quality and safety, and strive to provide patients with the safest and highest quality products. Quality manufacturing is one of the core pillars of Zhaoke, passing the on-site inspection by the NMPA is a strong accreditation for the Company. It affirms all the hard work that we have put in over the years to ensure a quality manufacturing system."
The Company has submitted the abbreviated new drug application (ANDA) for both of the aforementioned generic drugs (Bimatoprost Timolol eye drop and Epinastine HCl eye drop) to NMPA. The Company expects to commence commercialization of these two products upon receiving their regulatory approvals in 2022. Their commercialization is expected to address the unmet needs by glaucoma patients and help the Company forge a close bond with downstream strategic channels such as partners, key opinion leaders, ophthalmologists and hospitals.
About Zhaoke Ophthalmology Limited Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. The Company has built a comprehensive ophthalmic drug pipeline of 25 candidates, comprising 13 innovative drugs and 12 generic drugs, that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. The Company has developed internal capabilities in key aspects of ophthalmic drug development. The Company's specialized in-house research, development, clinical and regulatory capabilities have enabled it to concurrently advance multiple innovative and generic drug candidates through the preclinical and clinical stages. The Company has established a commercial-scale advanced manufacturing facility, which is designed and built for ophthalmic drugs in compliance with cGMP requirements of China, the United States and the European Union. The Company is led by an international management team with decades of industry experience and a track record of research and development, clinical operations, manufacturing, regulatory communications, business development and commercialization of ophthalmic therapies.
Zhaoke Ophthalmology has received strong endorsement from blue-chip pre-IPO investors, including GIC, Hillhouse Capital, TPG, Loyal Valley Capital, Orbimed and Aier Eye Hospital. The Company recently completed its HK IPO with cornerstone investors including CaaS Capital, GIC, Golden Valley, Jennison, Mass Ave, Matthews Asia, OrbiMed and VMS Investment.
Issued by Porda Havas International Finance Communications Group for and on behalf of Zhaoke Ophthalmology Limited. For further information, please contact:
Porda Havas International Finance Communications Group Zhaoke.hk@pordahavas.com
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Mitsubishi Heavy Industries Australia Expands Business Activities in Canberra Feb 27, 2025 11:10 JST
|  NEC establishes new policy to strengthen corporate governance with the aim of continuously enhancing corporate value Feb 27, 2025 10:45 JST
|  Olympus Announces Milestone for iTind(TM) Device with Expanded Availability Across Major APAC Markets Feb 26, 2025 11:00 JST
|  Fujitsu, ANA X, Toshiba Data, and Kawasaki City launch Japan's first pilot program to quantify citizen CO2 reduction Feb 25, 2025 11:24 JST
|  Mitsubishi and ENEOS to conduct Front End Engineering Design for Sustainable Aviation Fuel (SAF) Production at the Wakayama Refinery Feb 24, 2025 12:30 JST
|  Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026 Feb 22, 2025 04:50 JST
|  Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint Feb 21, 2025 19:40 JST
|  Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions Feb 21, 2025 19:11 JST
|  Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation Feb 21, 2025 15:01 JST
|  NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award Feb 21, 2025 14:39 JST
|  NEC Develops Near Real-time RIC for High Performance 5G vRAN Feb 21, 2025 12:00 JST
|  Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives Feb 20, 2025 13:29 JST
|  NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups Feb 19, 2025 20:16 JST
|  Mitsubishi Power Advances Bahrain's Industrial Growth with Completion of Alba's Power Station 5 Block 4 Combined Cycle Power Plant Project Feb 19, 2025 16:54 JST
|  Honda Reveals Specification for its Next-generation Fuel Cell Module Feb 19, 2025 11:07 JST
|  NEC Orchestrating Future Fund invests in Aetion, a U.S.-based provider of healthcare analytics platforms Feb 19, 2025 09:08 JST
|  Osaka Gas and MHI Launch CO2NNEX Digital Platform for Management and Transfer of Clean Gas Certificates for e-Methane, for Use during Expo 2025 Feb 18, 2025 13:18 JST
|  TOYOTA GAZOO Racing starts WEC season with Qatar challenge Feb 17, 2025 18:45 JST
|  FLAT OUT IN TOKYO "Red Bull Showrun x Powered by Honda" April 2 (Wed) Feb 17, 2025 16:21 JST
|  Thrilling TOYOTA GAZOO Racing one-two on Swedish snow Feb 17, 2025 14:23 JST
|
More Latest Release >>
|